Page 17 - Hpcsa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wall Street brokerages expect Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) to post earnings per share of ($0.18) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals reported earnings of ($0.90) per share in the same quarter last year, which indicates a positive year-over-year […]

Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality […]

David Motau was suspended after allegations of fraud and corruption were levelled against him in August last year

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 93,000 shares, a drop of 18.6% from the February 13th total of 114,300 shares. Based on an average trading volume of 36,300 shares, the short-interest ratio is presently 2.6 days. […]

Despite Beale no longer being on HPCSA register, the council said there are five pending cases for children’s deaths